Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards

Grifols announces mixed Q3 results 

By Brian Buntz | November 7, 2020

Grifols (MCE:GRF and NSDQ:GRFS) posted third-quarter earnings yesterday that came in ahead of analysts’ projections, but its revenue fell short of the consensus forecast.

The Barcelona-based manufacturer of blood-plasma products reported a net profit of €485.7 million on revenue of €4.0 billion for the quarter ended Sept. 30, 2020. Growth in constant currency was 7.6% compared with Q3 2019.

Grifols’ Earnings per share totaled €0.39 on revenue of €1.35B. Analysts had expected EPS of €0.26 on revenue of €1.37B.

In prepared remarks, the company’s co-chief financial officers, Raimon Grífols and Víctor Grífols Deu, were optimistic about the potential of blood-plasma treatments for COVID-10. The company’s leadership is “deeply confident in the potential of plasma and its derived medicines to combat the SARS-CoV-2 virus,” they wrote.

The company is developing hyperimmune immunoglobulin using plasma from COVID-19 patients.

Grífols did not provide concrete guidance for the rest of the year in its Q3 earnings report, although it stated that it had launched an operating expense containment plan that it expects to save €100 million by the end of the year.

Investors reacted to the company’s Q3 news by sending GRFS shares up 1.7% to $18.42 at the end of the trading day on Nov. 5. The company’s stock ended up flat on Nov. 6.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Catalent
Catalent to acquire Acorda’s manufacturing and packaging operations 
Endress
Endress+Hauser invests $4.5 million in U.S. sales and service support 
Festo
Festo launches compact rotary gripper for high-speed vial and microplate handling
Lantheus Holdings
Lantheus sells radiopharmacy and PET manufacturing facility to PharmaLogic

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Pharmaceutical Processing World
  • Enews Signup
  • Contact Us
  • About Us
  • R&D World
  • DeviceTalks
  • Drug Discovery & Development
  • Drug Delivery Business News
  • MassDevice
  • Medical Design Sourcing

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards